Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MEDIPHARM LABS CORP (LABS.CA) Stock Price & Overview
TSX:LABS • CA58504D1006
Current stock price
0.09 CAD
0 (0%)
Last:
The current stock price of LABS.CA is 0.09 CAD. Today LABS.CA is down by 0%. In the past month the price increased by 38.46%. In the past year, price increased by 5.88%.
LABS.CA Key Statistics
52-Week Range0.06 - 0.11
Current LABS.CA stock price positioned within its 52-week range.
1-Month Range0.06 - 0.1
Current LABS.CA stock price positioned within its 1-month range.
- Market Cap
- 38.237M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.03
- Dividend Yield
- N/A
LABS.CA Stock Performance
Today
0%
1 Week
+38.46%
1 Month
+38.46%
3 Months
+38.46%
Longer-term
6 Months +20.00%
1 Year +5.88%
2 Years +12.50%
3 Years +28.57%
5 Years -82.69%
10 Years N/A
LABS.CA Stock Chart
LABS.CA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LABS.CA. When comparing the yearly performance of all stocks, LABS.CA turns out to be only a medium performer in the overall market: it outperformed 67.19% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
LABS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LABS.CA. LABS.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LABS.CA Earnings
On March 30, 2026 LABS.CA reported an EPS of 0 and a revenue of 11.06M. The company missed EPS expectations (-145.1% surprise) and missed revenue expectations (-8.27% surprise).
Next Earnings DateMay 18, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-CA$0.01
Revenue Reported11.062M
EPS Surprise -145.10%
Revenue Surprise -8.27%
LABS.CA Forecast & Estimates
For the next year, analysts expect an EPS growth of 68.62% and a revenue growth -15.76% for LABS.CA
Analysts
Analysts42.22
Price TargetN/A
EPS Next Y68.62%
Revenue Next Year-15.76%
LABS.CA Financial Highlights
Over the last trailing twelve months LABS.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 35% compared to the year before.
Income Statements
Revenue(TTM)45.12M
Net Income(TTM)-8.27M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.07% | ||
| ROE | -23.08% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%-8.14%
EPS 1Y (TTM)35%
Revenue 1Y (TTM)7.54%
LABS.CA Ownership
Ownership
Inst OwnersN/A
Shares424.86M
Float389.52M
Ins Owners8.28%
Short Float %N/A
Short RatioN/A
LABS.CA Industry Overview
LABS.CA operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 30 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
46/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
28%
Outperformed 28% of sub-industries
3 Month Rank
64%
Outperformed 64% of sub-industries
6 Month Rank
28%
Outperformed 28% of sub-industries
Industry Fundamentals & Breadth
- Members
- 30
- New Highs
- 3.3%
- New Lows
- 10%
- Average ROE
- 17.4%
- Average Profit Margin
- 31.5%
- Average Operating Margin
- 20.4%
- Average P/E
- 5.1
- Average Fwd P/E
- 16.7
- Average Debt/Equity
- 0.5
LABS.CA Competitors/Peers
The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.3 | 2.864B | ||
| CRON | CRONOS GROUP INC | 39.84 | 1.358B | ||
| TLRY | TILRAY BRANDS INC | N/A | 976.689M | ||
| DHT-UN | DRI HEALTHCARE TRUST | 5.23 | 899.577M | ||
| GUD | KNIGHT THERAPEUTICS INC | 43.97 | 740.127M | ||
| WEED | CANOPY GROWTH CORP | N/A | 692.938M | ||
| DHT-U | DRI HEALTHCARE TRUST | 3.86 | 664.642M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 17.37 | 451.501M | ||
| TSND | TERRASCEND CORP | N/A | 379.358M | ||
| HITI | HIGH TIDE INC | 15.7 | 292.707M | ||
| ACB | AURORA CANNABIS INC | 58.42 | 267.671M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.31 | 263.136M | ||
| CRDL | CARDIOL THERAPEUTICS INC-A | N/A | 205.749M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About LABS.CA
Company Profile
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.
Company Info
IPO: 2018-02-09
MEDIPHARM LABS CORP
151 John Street
Barrie ONTARIO L4N 2L1 CA
CEO: Patrick McCutcheon
Employees: 127
Phone: 17057197425
MEDIPHARM LABS CORP / LABS.CA FAQ
What does MEDIPHARM LABS CORP do?
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.
What is the current price of LABS stock?
The current stock price of LABS.CA is 0.09 CAD.
What is the dividend status of MEDIPHARM LABS CORP?
LABS.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of LABS stock?
LABS.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is MEDIPHARM LABS CORP (LABS.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LABS.CA.
What is the expected growth for LABS stock?
The Revenue of MEDIPHARM LABS CORP (LABS.CA) is expected to decline by -15.76% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of LABS stock?
MEDIPHARM LABS CORP (LABS.CA) has a market capitalization of 38.24M CAD. This makes LABS.CA a Nano Cap stock.